Braveheart Bio (NASDAQ:BRVE) Director Erez Chimovits Acquires 1,940,000 Shares of Stock

Braveheart Bio, Inc. (NASDAQ:BRVE) Director Erez Chimovits acquired 1,940,000 shares of the firm’s stock in a transaction on Friday, August 7th. The shares were bought at an average cost of $18.00 per share, for a total transaction of $34,920,000.00. Following the acquisition, the director owned 11,901,826 shares in the company, valued at approximately $214,232,868. The trade was a 19.47% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Braveheart Bio Stock Down 9.2%

Shares of NASDAQ BRVE opened at $25.01 on Wednesday. Braveheart Bio, Inc. has a 1-year low of $24.61 and a 1-year high of $32.00.

About Braveheart Bio

We are a clinical‑stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB‑1893, is a next-generation oral small‑molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non‑obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.